Okada et al. [46] reported that the JNK inhibitor AS602801 could decrease the viability, self-renewal, and tumor-initiating capacity of CSC in pancreatic cancer, non-small cell lung cancer, ovarian cancer, and glioblastoma in vitro. This evidence concerns the gene MAPK8 and ovarian carcinoma.